Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667004 | 0.87 | IL4I1 (0.37) | ALDH1A1PRMT5WDR77PKMMAPK1 | |
| SCHEMBL31667648 | 0.87 | IL4I1 (0.37) | ALDH1A1PRMT5WDR77PKMMAPK1 | |
| SCHEMBL31667444 | 0.87 | IL4I1 (0.37) | ALDH1A1PRMT5WDR77PKMMAPK1 | |
| SCHEMBL31667082 | 0.83 | ALDH1A1 (0.36) | ALDH1A1PRMT5WDR77PKMMAPK1 | |
| SCHEMBL31666987 | 0.82 | PRMT5 (0.36) | ALDH1A1GAAHTTNPSR1PRMT5 | |
| SCHEMBL31667139 | 0.80 | PRMT5 (0.34) | ALDH1A1PRMT5WDR77PKMMAPK1 | |
| SCHEMBL31667569 | 0.80 | ALDH1A1 (0.33) | ALDH1A1PRMT5WDR77PKMMAPK1 | |
| SCHEMBL31667200 | 0.78 | ALDH1A1 (0.40) | ALDH1A1GAAHTTNPSR1PRMT5 | |
| SCHEMBL31667124 | 0.77 | ALDH1A1 (0.35) | ALDH1A1GAAHTTNPSR1PRMT5 | |
| SCHEMBL31667164 | 0.77 | MAPT (0.40) | ALDH1A1GAAHTTNPSR1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | ALDH1A1 2719/4885GAA 3156/4885HTT 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.